



Pathway discovery and engineering for cleavage of a ß-1 lignin-derived biaryl compound 
Gerald N. Presley1,2,‡,†, Allison Z. Werner2,4,†, Rui Katahira4, David C. Garcia5, Stefan J. Haugen4, Kelsey J. Ramirez4, Richard J. 
Giannone2,3, Gregg T. Beckham2,4,*, and Joshua K. Michener1,2,* 
 
1Biosciences Division, 2Center for Bioenergy Innovation, and 3Chemical Sciences Division, Oak Ridge National Laboratory, Oak 
Ridge, TN, 37830; 4Renewable Resources and Enabling Sciences Center, National Renewable Energy Laboratory, Golden, CO 
80401; 5The Bredesen Center for Interdisciplinary Research and Graduate Education, University of Tennessee, Knoxville, TN, 
37996. 
 
† These authors contributed equally to this work 
‡ Current address: Department of Wood Science and Engineering, Oregon State University, Corvallis, OR 
* Correspondence should be addressed to JKM (michenerjk@ornl.gov) or GTB (gregg.beckham@nrel.gov) 
  
 2 
Supplemental Tables.  
 
Table S1. DNA sequences of oligonucleotides and gBlocks used in this study.  
















Construct for deletion of RS14230 
from N. aromaticivorans 
DSM12444. Upstream and 
downstream homology arms are 
shown in blue and red, 

















Construct for deletion of RS14250 
from N. aromaticivorans 
DSM12444. Upstream and 
downstream homology arms are 
shown in blue and red, 















(OptimumGene™) RS14230 DNA 
sequence for expression in E. coli. 
The open reading frame is shown 
in dotted underline. Fragment 


























(OptimumGene™) RS14250 DNA 
sequence for expression in E. coli. 
The open reading frame is shown 
in dotted underline. Fragment 














Codon optimized (Optimizer) 
RS14230 DNA sequence for 
expression in P. putida 
(CAI=0.72). The open reading 
frame is shown in dotted 
underline. RBS was designed in 
RBSCalculator (double 
underlined, AU=10070). XbaI and 
SpeI cut-sites (underlined) and six 
random base pairs inserted 



























Codon optimized (IDT) RS14250 
DNA sequence for expression in 
P. putida in IDT’s codon 
optimization tool. The open 
reading frame is shown in dotted 
underline. RBS was designed in 
RBSCalculator (double 
underlined, AU=10522). XbaI and 
SpeI cut-sites (underlined) and six 
random base pairs inserted 
flanking. gBlock ordered from 
IDT. 
RS14230 
SeqF GTGATGCAGTTTGACCACACC Primer set for sequence 
confirmation of RS14230 deletion 
in JMN18 RS14230 
SeqR ATCATCGGTTTGAGCTTCTTCTGC 
RS14250 
SeqF CAGGATCATCGCATCGGCATAG Primer set for sequence 
confirmation of RS14230 deletion 
in JMN19 RS14250 
SeqR TTTGCCCACATCGACATTTCCG 
oAW046 ggaattgtgagcggataacaatttcacacTCTAGAACAATTAATAGGCTAAGGCCATAAGGACAACTTTATGA Primer set for amplification of RS14230 (gAW002) with 5’ 
overlap (oAW046, underlined) to 
RS14230 and 3’ overlap (oAW060, 
underlined) to fpvA region for HiFi 
Assembly of pAW001. oAW060 cctgcttagggttggtttttgagcggccgcCGGCCACTTCTTCTGCAGTTTGG 
oAW061 caaactgcagaagaagtggccggcggccgcTCAAAAACCAACCCTAAGCAGGAATTCTATGG Primer set for amplification of RS14250 (gAW004) with 5’ 
overlap (oAW061, underlined) to 
RS14230 and 3’ overlap (oAW059, 
underlined) to fpvA region for HiFi 
Assembly of pAW001. oAW059 atgagtaaaaagcctccggtcggaggcttttgactACTAGTGGCAGCCGACCC 
oAW027 GTACTACCAGGGCATTGCC pAW001 sequencing 
oAW029 GCCGTTTCCGTGGTATC pAW001 sequencing 
oAW031 GACGGCACATGTCCG pAW001 and pAW008 sequencing 
oAW062 GACGGCATGGTGAGC pAW001 sequencing 
oAW063 GGGTGGATGTTGTCGATG pAW001 sequencing 
oAW103 catacacgcacgagatttatggggccatttGCGGCCGCGAGCTGTTGACAATTAATCATCGGCTCGTATAATG 
Primer set for amplification of 
RS14230-RS14250 expression 
cassette (from pAW001) with 5’ 
overlap (oAW103, underlined) to 
crc HR_up and 3’ overlap 
(oAW104, underlined) to crc 
HR_dn region for HiFi Assembly 
of pAW008. 
oAW104 ggggctgcaatgcagccccaatggccttGCGGCCGCGGCAGCCGACCCTTCCAATGCGTCCAG 
oAW077 GAACTGGAGGACTTGAACGC pAW008 sequencing 
oAW105 CAAGCCGGCATTGAAGAAATACG pAW008 sequencing 
oAW157 CAGACCGCCTCCTGCCAGAAACC pAW008 sequencing 
oAW158 GATCCACATGGGCCCTCAAGAC pAW008 sequencing 
oAW023 ACATCACCTGCTACGAAGC Colony PCR for AW006  
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oAW024 GATTCGCATGACACGCTG (3634 bp, Tm=72°C) 
oAW080 CGTGTGATCATTTTCGAAGCG Colony PCR for AW049 




Table S2.  Plasmids and strains used in this study.  
PLASMIDS 
Name Utility or Genotype Description/Construction Details Reference 
pAK405 
To genetically modify the chromosome of 
N. aromaticivorans via homologous 
recombination 
Vector backbone allowing markerless chromosomal modifications in diverse sphingomonads. 
Uses kanamycin for initial selection and streptomycin for counterselection. 
1 
pJM296 To delete RS14230 from N. aromaticivorans Includes the synthesized sequence NaRS14230 above This study 
pJM297 To delete RS14250 from N. aromaticivorans Includes the synthesized sequence NaRS14250 above This study 
pET-22b E. coli expression vector Contains a T7 promoter for gene expression, a pBR322 origin of replication, and an ampicillin selection marker Novagen 
pET22b-lsdA Heterologous expression of LsdA in E. coli Includes the synthesized sequence EcRS14250 above This study 
pET22b-lsdE Heterologous expression of LsdE in E. coli Includes the synthesized sequence EcRS14230 above This study 
pK18mobsacB 
To genetically modify the chromosome of 
P. putida KT2440 via homologous 
recombination 
“Cloning vector allowing mobilization into a wide range of Gram- and 
Gram+ bacteria. After mobilization, the plasmid can be maintained by integration into the 
host chromosome via homologous recombination. Excision of the intervening plasmid 
sequence by a double crossover event can be facilitated by selection on medium containing 
10% sucrose. The sacB gene has been modified to eliminate the HindIII and EcoRI sites in 
the coding region.” 
ATCC® 
87097™ 
pCJ033 To integrate DNA into the crc genomic locus in P. putida KT2440 
As described in: Johnson, C. W., Abraham, P. E., Linger, J. G., Khanna, P., Hettich, R. L., 
Beckham, G. T., Eliminating a global regulator of carbon catabolite repression enhances the 
conversion of aromatic lignin monomers to muconate in Pseudomonas putida KT2440. 
Metabolic Engineering Communications, Vol. 5, 2017, pp. 19-25.  
2 
pCJ107 To integrate DNA into the fpvA genomic locus in P. putida KT2440 
As described in Salvachúa, D., Johnson, C. W., Singer, C. A., Rohrer, H., Peterson, D. J., 
Black, B. A., Knapp, A., Beckham, G. T., 2018. Bioprocess development for muconic acid 
production from aromatic compounds and lignin. Green Chem. 20, 5007-5019. 
3 
pAW001 
To integrate a codon optimized RS14230 
and RS14250 expression cassette into the 
P. putida KT2440 genome at the fpvA 
locus 
The RS14230 amino acid sequence was codon optimized for expression in P. putida using 
Optimizer’s guided random method; 4  the RS14250 amino acid sequence optimized with 
Optimizer contained a prohibitively high GC content for synthesis and therefore was 
optimized using Integrated DNA Technology’s codon optimization tool (www.idtdna.com) 
(Table S1). Ribosome binding sites were designed for each gene using the RBSCalculator 
and the two-gene operon was driven by the constitutive tac promoter (Ptac). Both genes with 
their respective RBS were synthesized as gBlocks (IDT Corp.). gBlocks were amplified using 
Q5® Hot Start High-Fidelity DNA Polymerase (NEB, Inc.) and oligos as listed in Table S1, 
purified with the QIAquick PCR Purification Kit (ThermoFisher Scientific), assembled with 
HiFi DNA Assembly (NEB, Inc.) into XbaI/SpeI-digested pCJ107, and transformed into 
NEB® E. coli 5α F’Iq. The plasmid was sequence verified using oAW027, oAW029, 
oAW031, oAW062, and oAW062 (GENEWIZ.com).  
This study 
pAW008 
To integrate a codon optimized RS14230 
and RS14250 expression cassette into the 
P. putida KT2440 genome at the crc locus 
with simultaneous crc deletion 
The RS14230 and RS14250 expression cassette was amplified from pAW001 with oAW103 
and oAW104, assembled into pCJ033 digested with NotI with HiFi DNA Assembly (NEB, 
Inc.), and transformed into NEB® E. coli 5α F’Iq. Construction was confirmed via colony 
PCR using oAW105 and oAW106 (2.8 kB, Tm=°56) and sequence verified using oAW031, 
oAW077, oAW105, oAW157, and oAW158 (GENEWIZ.com).  
This study 
STRAINS 
Escherichia coli  
BL21 Star 
(DE3) 
F- ompT hsdSB (rB-, mB-) gal dcm rne131 




NEB® 5α F’Iq 
F´ proA+B+ lacIq ∆(lacZ)M15 
zzf::Tn10 (TetR) / fhuA2∆(argF-
lacZ)U169 phoA glnV44 Φ80Δ(lacZ)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
Host for pK18mobsacB-based vectors (ATCC® 87097™) NEB Cat. #C2992I 
Novosphingobium aromaticivorans 
DSM12444 Novosphingobium aromaticivorans (N. aromaticivorans) F199  Wild-type N. aromaticivorans DSM12444  
JMN2 Evolved mutant of N. aromaticivorans F199 Evolved mutant of DSM12444 This study 
JMN18 N. aromaticivorans JMN2 ∆RS14250 (lsdA) RS14230 was deleted using pJM296. Deletion was confirmed with RS14230 SeqF/SeqR. This study 
JMN19 N. aromaticivorans JMN2 ∆RS14230 (lsdE) RS14250 was deleted using pJM297. Deletion was confirmed with RS14250 SeqF/SeqR. This study 
Pseudomonas putida 
KT2440 P. putida KT2440  Wild-type P. putida KT2440 ATCC® 47054™ 
AW006 P. putida KT2440 fpvA:Ptac:RS14230:RS14250 
pAW001 was transformed into KT2440. Integration was confirmed by colony PCR with 
oAW023 and oAW024 (3.6 kB product, Tm=72°C).  This study 
CJ475 
P. putida KT2440 ΔcatRBC::Ptac:catA 
ΔpcaHG::Ptac:aroY:ecdBD 
fpvA:Ptac:vanAB 
As described in: Salvachúa, D., Johnson, C. W., Singer, C. A., Rohrer, H., Peterson, D. J., 
Black, B. A., Knapp, A., Beckham, G. T., 2018. Bioprocess development for muconic acid 








pAW008 was transformed into CJ475. Integration was confirmed by colony PCR with 
oAW080 and oAW105 (1.3 kB, Tm=65°C). This study 
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 Table S3. Optimized quantifying and qualifying multiple reaction monitoring (MRM) transitions for liquid chromatography-
electrospray ionization tandem mass spectrometry analysis. 











tGG bDAP 319.1 [M-H]- 319.1  271 8 95 241 28 
eGG bDAP 319.1 [M-H]- 319.1  271 8 85 212.9 40 
tHH bDAP 259.1 [M-H]- 259.1  211 8 95 117 72 
eHH bDAP 259.1 [M-H]- 259.1  211 8 95 182 44 
4-Hydroxybenzoic Acid 137 [M-H]- 137  93 16 70 65.1 36 
4-Hydroxybenzaldehyde 121 [M-H]- 121  120 20 98 92 28 
Vanillic Acid 167 [M-H]- 167  152 12 89 108 20 







Figure S1. Scheme for the synthesis of the HH β-1 dimer, 1,2-di(p-hydroxyphenyl)propane-1,3-diol (DHPD, compound 7E/7T, 
7E: erythro, 7T: threo) was prepared from p-hydroxybenzaldehyde (1) in 5 steps, similar to a previous synthesis.5 Benzylated 
methyl 4-hydroxyphenylacetate (4) was condensed with benzylated p-hydroxybenzaldehyde (2) to obtain γ-methyl ester (5) with 
55.3 mol% yield, including erythro and threo isomers. The γ-methyl ester was reduced to γ-hydroxymethyl dimer (6) using DIBAL 
at 0°C with 62.6 mol% yield for the threo isomer and 92.1 mol% yield for the erythro isomer. The phenolic-OH group in compound 
6 was deprotected to obtain DHPD (7) at a 94.0 mol% yield for the threo isomer (7T) and a 56.6 mol% yield for the erythro isomer 






Figure S2. Scheme for the synthesis of the GG β-1 dimer, 1,2-diguaiacylpropane-1,3-diol (DGPD, compound 14E/14T, 14E: 
erythro, 14T: threo). Benzylated methyl 4-hydroxy-3-methoxyphenylacetate (11) was condensed with benzylated vanillin (9) to 
obtain γ-methyl ester (12) with a 47.5 mol% yield, including erythro and threo isomers. The γ-methyl ester was reduced to γ-
hydroxymethyl dimer (13) using DIBAL at 0°C at a 55.9 mol% yield for the threo isomer and a 27.0 mol% yield for the erythro 
isomer. The phenolic-OH group in compound 13 was deprotected to obtain DGPD (14) with 94.4 mol% yield of the threo isomer 














































































































Figure S18.  Evolved N. aromaticivorans strain JMN2 shows improved growth with a variety of lignin-derived aromatic compounds. Wildtype 
DSM12444 and evolved JMN2 were grown in minimal medium with 1 g/L of either (a) GGE or (b) p-coumaric acid as the sole carbon source. 




Figure S19. In minimal medium, DGPD consumption by JMN2 is growth-associated. Strain JMN2 was grown in minimal medium with DGPD 
as the sole carbon source. Cultures were assayed every 24 hours for cell growth and residual DGPD concentration. Error bars show one standard 




Figure S20. (a) Maximum-likelihood phylogenetic tree of LsdE sequences. Representative strains from the major branches are highlighted in red 
and were examined in more detail. (b) Genomic arrangement of lsdE and lsdA in selected genome sequences. Genes for the PCA 4,5-cleavage 




Figure S21. LC-MS analysis of DGPD stock identifies trace contamination with vanillin. The DGPD stock used for experiments with E. coli 




Figure S22. Growth of (a) P. putida wild-type and (b) AW006 (P. putida fpvA::Ptac:lsdT:lsdA) in M9 minimal media supplemented with 20 mM 
glucose and 2% (v/v) methanol. Metabolite concentrations of all analytes and growth (optical density, 600nm) are plotted. Error bars represent the 






Figure S23. Metabolite concentration and growth (OD600) across the 96 h experiment. Wild-type P. putida or AW006 (P. putida fpvA::Ptac:RS14230:RS14250) cultivations were performed in M9 
minimal media supplemented with 20 mM glucose and (a) erythro-DGPD (eDGPD), (b) threo-DGPD (tDGPD), (c) erythro-DHPD (eDHPD), or (d) threo-DHPD (tDHPD). Metabolites were quantified 
from the cultivation supernatant. Error bars represent the standard deviation across biological triplicates. Abbreviations: 4-HBAld, 4-hydrobenzaldehyde; 4-HBA, 4-hydroxybenzoate; OD600, optical 





Figure S24. Dimer conversion (%) after 24 h (∆24 h), 48 h (∆48 h), or 72 h (72 h) for wild-type P. putida or AW006 (P. putida fpvA::Ptac:lsdT:lsdA) 
cultivated in M9 minimal medium supplemented with 20 mM glucose and (a) erythro-DGPD, (b) threo-DGPD, (c) erythro-DHPD, or (d) threo-
DHPD. Error bars represent the standard deviation across biological triplicates. * indicates p≤0.05 and n.s. indicates p>0.05 from a paired one-





Figure S25. Metabolite concentration over time in non-inoculated controls. Cultivations without the addition of cells were performed in M9 minimal 
media supplemented with 20 mM glucose and (a) erythro-DGPD, (b) threo-DGPD, (c) erythro-DHPD, or (d) threo-DHPD. Error bars represent 






Figure S26. Growth and metabolite concentration across 96 h of AW049 (P. putida KT2440 ΔcatRBC::Ptac:catA ΔpcaHG::Ptac:aroY:ecdBD 
Δcrc::Ptac:lsdT:lsdA fpvA::Ptac:vanAB) cultivations in M9 minimal media supplemented with 20 mM glucose and 0.35 mM erythro-DGPD 
(eDGPD). Glucose was fed to 20 mM every 24 h. Metabolites were quantified from the cultivation supernatant. Muconate was quantified as both 
cis,cis- (cc Muconic acid) and cis,trans- (ct Muconic acid) muconic acid. Error bars represent the standard deviation across biological triplicates.  
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Supplemental Text  
 
SI Text 1. Dimer synthesis and NMR acquisition details. See Scheme 1-2 (Figure S1-S2) for compound number references.  
 
General information for synthesis of model compounds 
All chemicals and solvents were used without additional purification. Flash chromatography was performed using Teledyne CombiFlash equipped 
with Teledyne 80 and 120 g prepared column for further purification. Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker 
AVANCE 400 MHz spectrometer equipped with a 5 mm BBO probe (1H 400 MHz, 13C 100 MHz). Chemical shifts for 1H NMR spectra are reported 
in parts per million (ppm) from tetramethylsilane as a reference of 0 ppm. 1H-NMR spectra were recorded with a relaxation delay 1.0 s and an 
acquisition time of 4.09 s with 64 scans. Chemical shifts for 13C NMR spectra are reported in ppm from the solvent as a reference (CDCl3: δ 77.23 
ppm, (CD3)2CO: 29.92 ppm, CD3OD: 49.15 ppm). The acquisition parameters for 13C-NMR included a 90° pulse width, a relaxation delay 1.0 s 
and an acquisition time of 1.36 s with 1024 scan. 2D-NMR spectra [gradient correlation spectroscopy (gCOSY), heteronuclear single quantum 
coherence (HSQC)] were recorded using standard Bruker implementation. 
 
Synthesis method for 1,2-di(p-hydroxyphenyl)propane-1,3-diol (compound 7, DHPD) 
Benzylation (compound 2) 
To the solution of 4-hydroxybenzaldehyde (10.0 g, 82.3 mmol) in DMF (5 mL), benzyl bromide (12.0 mL, 98.7 mmol), potassium carbonate (17.1 
g, 123.4 mmol) and potassium iodate (1.36 g, 8.23 mmol) were added at room temperature. After stirring for 19.5 hours, the reaction mixture was 
filtered to remove excess K2CO3. The reaction mixture was diluted with deionized H2O and extracted with ethyl acetate three times. The organic 
layer was washed with brine two times and then dried over Na2SO4. A crude oil obtained was recrystallized from ethanol to yield a white powder 
(compound 2, 13.1 g) with 76.6 mol% yield.  
 
Benzylation (compound 4, Figure S3) 
Compound 3 was benzylated in the same method of compound 2. To the solution of methyl 4-hydroxyphenylacetate (compound 3, 3.0 g, 18.1 
mmol) in DMF (5 mL), benzyl bromide (2.64 mL, 21.7 mmol), potassium carbonate (3.75 g, 27.2 mmol) and potassium iodate (0.3 g, 1.81 mmol) 
were added at room temperature. After stirring for 22 hours, the reaction mixture was treated in the same manner as compound 1. The reaction 
mixture was recrystallized from mixture of ethyl acetate and hexane to obtain a white powder (compound 4, 2.48 g, 56.1 mol%). 1H NMR (400 
MHz, CDCl3) δ 7.29-7.43 (5H, m), 7.19 (2H, d, J=8.6Hz, Arom-H), 6.93 (2H, d, J=8.6Hz, Arom-H), 5.04 (2H, s, CH2), 3.68 (3H, s, COOCH3), 
3.56 (2H, s, Hα). 13C NMR (100 MHz, CDCl3) δ 172.5 (Cβ), 158.2, 137.2, 130.5, 128.8, 128.1, 127.6, 126.6, 115.2, 70.2 (CH2), 52.2 (COOCH3), 
40.5 (Cα) ppm. 
 
Coupling (compound 5, Figure S4-5) 
To the solution of lithium diisopropylamide (2 M in THF, 3.73 mL, 7.46 mmol) in anhydrous THF (10 mL), benzylated methyl 4-O-
benzylphenylacetate (compound 4, 0.91 g, 3.73 mmol) in anhydrous THF (10 mL) was added dropwisely for over 15 min at -78°C. After stirring 
for 30 min, benzylated vanillin (compound 2, 0.79 g, 3.73 mmol) was added drop-wise for over 1 hour. After stirring for 2 hours, the reaction 
solution was heated from -78°C to ambient temperature, and quenched by addition of H2O (50 mL). The reaction mixture was acidified with 1 N 
HCl, extracted with ethyl acetate three times, washed with brine, and dried over Na2SO4. A crude oil was purified by a silica gel column to obtain 
of γ-methyl ester (compound 5) with the threo isomer (0.682 g, 39.1 mol%) and the erythro isomer (0.283 mg, 16.2 mol%). Threo isomer (5T): 1H 
NMR (400 MHz, CDCl3) δ 7.27-7.39 (10H, m), 7.01 (2H, d, J=8.7Hz, Arom-H), 6.98 (2H, d, J=8.7Hz, Arom-H), 6.78 (2H, d, J=8.8Hz, Arom-H), 
6.77 (2H, d, J=8.8Hz, Arom-H), 5.08 (H, dd, J=9.4, 3.8Hz, Ha), 4.98 (2H, s, CH2), 4.96 (2H, s, CH2), 3.79 (H, d, J=9.4Hz, Hb), 3.71 (3H, s, 
COOCH3), 2.92 (H, d, J=3.8Hz, OH). 13C NMR (100 MHz, CDCl3) δ 174.4 (Cγ), 158.5, 158.3, 137.1, 137.0, 133.5, 129.8, 128.8, 128.7, 128.2, 
128.1, 128.0, 127.9, 127.7, 127.6, 115.0, 114.7, 76.4 (Cα), 70.1 (CH2), 59.3 (Cβ), 52.5 (COOCH3) ppm. Erythro isomer (5E): 1H NMR (400 MHz, 
CDCl3) δ 7.17-7.36 (10H, m), 7.18 (4H, dd, J=19.2, 8.7Hz), 6.85 (4H, dd, J=14.0, 8.7Hz), 5.11 (H, dd, J=7.8, 2.1Hz, Hα), 4.98 (2H, s, CH2), 4.97 
(2H, s, CH2), 3.71 (H, d, J=7.8Hz, Hβ), 3.44 (3H, s, COOCH3), 2.36 (H, d, J=2.3Hz). 13C NMR (100 MHz, CDCl3) δ 173.2 (Cγ), 158.8, 158.7, 
137.2, 137.1, 133.6, 130.4, 128.8, 128.7, 128.22, 128.16, 128.1, 127.7, 127.3, 115.2, 114.8, 74.9 (Cα), 70.2 (CH2), 70.1 (CH2), 59.1 (Cβ), 52.2 
(COOCH3) ppm. 
 
Reduction (compound 6, Figure S6-7) 
To a solution of the γ-methyl ester (compound 5T, threo isomer, 0.62 mg, 1.32 mmol) in anhydrous dichloromethane (15 mL), DIBAL in DCM 
(5.3 mL, 5.3 mmol) was added drop-wise at 0°C. After stirring for 4 hours at the same temperature, deionized H2O (20 mL) was added to quench 
the reaction. The reaction mixture was gelated by acidification with saturated citric acid. After dilution with deionized H2O (30 mL), the solution 
was extracted with ethyl acetate (50 mL) three times. The combined organic layer was washed with brine and dried over Na2SO4. A crude oil was 
recrystallized from mixture of ethyl acetate and hexane to obtain a white powder (compound 6T, threo isomer, 0.365 g, 62.6 mol%). The erythro 
isomer of compound 5E was reduced in the same way to obtain a white crystal with 92.1 mol% yield. Threo isomer (6T): 1H NMR (400 MHz, 
(CD3)2CO) δ 7.20-7.36 (10H, m), 6.91-7.03 (4H, m, Arom-H), 6.69-6.74 (4H, m, Arom-H), 4.93 (2H, s, CH2), 4.92 (2H, s, CH2), 4.89 (H, dd, J=8.8, 
3.2Hz, Hα), 4.00 (H, m, Hγ), 3.79 (H, m, Hγ), 2.98 (H, m, Hβ). 13C NMR (100 MHz, (CD3)2CO) δ 158.7, 158.3, 138.6, 138.5, 137.6, 133.9, 130.7, 
129.3, 129.0, 128.6, 128.5, 128.4, 115.1, 114.8, 78.4 (Cα), 70.3 (CH2), 66.6 (Cγ), 55.4 (Cβ) ppm. Erythro isomer (6E): 1H NMR (400 MHz, CDCl3) 
δ 7.23-7.37 (10H, m), 7.06-7.11 (4H, m, Arom-H), 6.83-6.89 (4H, m, Arom-H), 4.98 (4H, s, 2xCH2), 4.83 (H, d, J=7.2Hz, Hα), 3.63 (2H, m, Hγ), 
3.01 (H, dt, J=7.2, 6.6Hz, Hβ). 13C NMR (100 MHz, CDCl3) δ 158.7, 158.4, 137.2, 137.1, 134.7, 131.0, 130.3, 128.8, 128.2, 128.1, 127.7, 127.6, 
115.3, 115.0, 75.7 (Cα), 70.3 (CH2), 64.5 (Cγ), 55.2 (Cβ) ppm. 
 
Deprotection (compound 7, DHPD, Figure S8-9) 
To the solution of compound 6T- threo (108 mg, 0.245 mmol) in 3 mL of methanol/THF (1:1, v/v), 10% Pd-C (72 mg) was added and stirred for 
6 hours under H2 atmosphere. The reaction mixture was filtered, and the filtrate was dried to obtain a white powder (compound 7T, 0.06 g, 94.0 
mol%). To the solution of compound 6E- erythro (0.2 g, 0.455 mmol) in 5 mL of methanol/THF (1:1, v/v), 10% Pd-C (80 mg) was added and 
stirred for 3 hours under H2 atmosphere to obtain white powder (compound 7E, 0.0669 g, 56.6 mol%). Threo isomer (7T): 1H NMR (400 MHz, 
(CD3)2CO) δ 6.85 (2H, d, J=8.5Hz, Arom-H), 6.74 (2H, d, J=8.5Hz, Arom-H), 6.46-6.50 (4H, m, Arom-H), 4.76 (H, d, J=8.8Hz, Hα), 3.95 (H, dd, 
J=10.8, 7.5Hz, Hγ), 3.72 (H, dd, J=10.8, 5.2Hz, Hγ), 2.88 (H, m, Hβ). 13C NMR (100 MHz, (CD3)2CO) δ 157.1 (C4), 156.6 (C4’), 135.8 (C1), 
132.0 (C1’), 130.5 (C2’,6’), 128.9 (C2,6), 115.7 (C3’,5’), 115.3 (C3,5), 78.8 (Cα), 66.8 (Cγ), 55.3 (Cβ) ppm. Erythro isomer (7E): 1H NMR (400 
 35 
MHz, CD3OD) δ 7.00 (2H, d, J=8.5Hz, Arom-H), 6.98 (2H, d, J=8.6Hz, Arom-H), 6.68 (2H, d, J=8.6Hz, Arom-H), 6.67 (2H, d, J=8.6Hz, Arom-
H), 4.87 (H, d, J=6.3Hz, Hα), 3.75 (H, dd, J=10.8, 6.2Hz, Hγ), 3.61 (H, dd, J=10.8, 7.4Hz, Hγ), 2.93 (H, dt, J=7.4, 6.5Hz, Hβ). 13C NMR (100 
MHz, CD3OD) δ 157.7 (C4), 157.1 (C4’), 135.9 (C1), 132.0 (C1’), 131.6 (C2’,6’), 129.0 (C2,6), 115.9 (C3’,5’), 115.8 (C3,5), 75.7 (Cα), 64.7 (Cγ), 
56.5 (Cβ) ppm.  
 
Synthesis method for 1,2-diguaiacylpropane-1,3-diol (compound 14, DGPD) 
Benzylation (compound 9)  
To the solution of vanillin (6.5 g, 42.7 mmol) in DMF (7 mL), benzyl bromide (6.16 mL, 51.3 mmol), potassium carbonate (8.86 g, 64.1 mmol) 
and potassium iodate (0.71 g, 4.27 mmol) were added at room temperature. After stirring for 20 hours, the reaction mixture was treated with the 
same purification protocol for compound 1 to yield white crystals (compound 9, 7.94 g) in a 76.9 mol% yield. 
 
Methyl ester (compound 10, Figure S10)  
To the solution of 4-hydroxy-3-methoxyphenyl acetic acid (2.0 g, 10.8 mmol) in methanol (25 mL), acetyl chloride (0.92 mL, 12.9 mmol) and 96% 
H2SO4 (1.5 mL) were added at room temperature. After refluxing for 18 hours, the reaction mixture was diluted with  deionized H2O (60 mL) and 
extracted with ethyl acetate (60 mL) four times. The combined ethyl acetate layer was washed with brine and then dried over Na2SO4. A crude oil 
was recrystallized from ethanol/hexane (1:1, v/v) to obtain a white powder (compound 10, 2.1 g, 97.5 mol%). 1H NMR (400 MHz, CDCl3) δ 6.72-
6.84 (3H, m), 5.82 (1H, s, OH), 3.82 (3H, s, OMe), 3.66 (3H, s, COOCH3), 3.53 (2H, s, Hα). 13C NMR (100 MHz, CDCl3) δ 172.6 (Cβ), 146.7, 
144.9, 125.8, 122.2, 114.6, 111.9, 55.9 (OMe), 52.1 (COOCH3), 40.8 (Cα) ppm. 
 
Benzylation (compound 11, Figure S11)  
Compound 10 was benzylated in the same method of compound 2. To the solution of methyl homovanillate (compound 10, 2.0 g, 10.3 mmol) in 
DMF (5 mL), benzyl bromide (1.51 mL, 12.4 mmol), potassium carbonate (2.14 g, 15.5 mmol) and potassium iodate (0.17 g, 1.03 mmol) were 
added at room temperature. After stirring for 21 hours, the reaction mixture was treated in the same manner as compound 1. The reaction mixture 
was recrystallized from ethanol to obtain a white powder (compound 11, 2.03 g, 68.5 mol%).1H NMR (400 MHz, CDCl3) δ 7.17-7.36 (5H, m), 
6.65-6.76 (3H, m, Arom-H), 5.06 (2H, s, CH2), 3.81 (3H, s, OMe), 3.61 (3H, s, COOCH3), 3.47 (2H, s, Hα). 13C NMR (100 MHz, CDCl3) δ 172.4 
(Cβ), 149.8, 147.5, 137.4, 128.7, 128.0, 127.4, 127.2, 121.5, 114.2, 113.1, 71.2 (CH2), 56.2 (OMe), 52.2 (COOCH3), 40.9 (Cα) ppm. 
 
Coupling (compound 12, Figure S12-13)  
To the solution of lithium diisopropylamide (2 M in THF, 5.4 mL, 10.8 mmol) in anhydrous THF (10 mL), benzylated methyl homovanillate 
(compound 11, 1.03 g, 3.6 mmol) in anhydrous THF (13 mL) was added drop-wise for over 1 hour at -78°C. After stirring for 1 hour, benzylated 
vanillin (compound 9, 1.05 g, 4.32 mmol) in anhydrous THF (13 mL) was added drop-wise for over 1 hour. After 27 hours of stirring, the reaction 
solution was heated from -78°C to room temperature, and quenched by addition of H2O (80 mL). The reaction mixture was acidified with 1 N HCl, 
extracted with ethyl acetate three times, washed with brine, and dried over Na2SO4. A crude oil was purified by flash chromatography to obtain of 
γ-methyl ester (compound 12) with threo isomer (0.630 g, 33.1 mol%) and erythro isomer (0.274 g, 14.4 mol%). Threo isomer (12T): 1H NMR 
(400 MHz, (CD3)2CO) δ 7.14-7.31 (10H, m), 6.51-6.69 (6H, m, Arom-H), 4.99 (H, dd, J=10.2, 4.1Hz, Hα), 4.88 (4H, s, 2xCH2), 3.66 (H, d, 
J=10.2Hz, Hβ), 3.56 (3H, s, OMe), 3.55 (3H, s, OMe), 3.54 (3H, s, COOCH3). 13C NMR (100 MHz, (CD3)2CO) δ 172.6 (Cγ), 149.1, 149.0, 147.2, 
147.1, 137.3, 137.2, 135.3, 128.6, 127.8, 127.7, 127.12, 127.09, 127.04, 127.03, 120.5, 118.8, 113.3, 113.0, 112.8, 110.7, 75.6 (Cα), 69.98 (CH2), 
69.95 (CH2), 59.3 (Cβ), 54.8 (OMe), 54.7 (OMe), 50.5 (COOCH3) ppm. Erythro isomer (12E): 1H NMR (400 MHz, CDCl3) δ 7.18-7.37 (10H, m), 
6.71-6.81 (6H, m, Arom-H), 5.09 (H, dd, J=7.6, 1.4Hz, Hα), 5.07 (2H, s, CH2), 5.06 (2H, s, CH2), 3.78 (3H, s, OMe), 3.73 (3H, s, OMe), 3.67 (H, 
d, J=7.6Hz, Hβ), 3.46 (3H, s, COOCH3). 13C NMR (100 MHz, CDCl3) δ 173.2 (Cγ), 149.9, 149.8, 148.3, 148.0, 137.4, 137.3, 128.8, 128.7, 128.1, 
128.0, 127.8, 127.5, 127.4, 121.7, 119.2, 114.1, 114.0, 112.9, 110.6, 75.1 (Cα), 71.3 (CH2), 71.2 (CH2), 59.4 (Cβ), 56.3 (OMe), 56.2 (OMe), 52.2 
(COOCH3) ppm. 
 
Reduction (compound 13, Figure S14-15)  
To the solution of LAH (229 mg, 5.73 mmol) in THF (5 mL), a solution of the γ-methyl ester (compound 12T, threo isomer, 381 mg, 0.722 mmol) 
in anhydrous THF (14 mL), was added drop-wise at 0°C for over 40 min. After stirring for 4 hours at the same temperature, the reaction mixture 
was allowed to warm to room temperature. Remaining LAH was quenched by adding deionized H2O (3 mL). After acidification with 1 N HCl, the 
reaction mixture was extracted with ethyl acetate (30 mL) four times. The combined organic layer was washed with brine and dried over Na2SO4. 
A crude oil was purified by preparative TLC with 5% acetone/DCM to obtain a white powder (compound 13T, threo isomer, 197 mg, 55.9 mol%). 
To a solution of the γ-methyl ester (compound 12E, erythro isomer, 104 mg, 0.196 mmol) in anhydrous DCM (15 mL), DIBAL in DCM (1.88 mL, 
1.88 mmol) was added drop-wise at 0°C for over 30 min. After stirring for 19.5 hours at the same temperature, deionized H2O (30 mL) was added 
to quench the reaction. The reaction mixture was gelated. The gel status was changed to liquid solution by acidification with saturated citric acid. 
The solution was extracted with ethyl acetate (30 mL) four times. Combined organic layer was washed with brine and dried over Na2SO4. A crude 
oil was purified by preparative TLC with 5% acetone/DCM to obtain a white powder (compound 13E, erythro isomer, 25.9 mg, 27.0 mol%). Threo 
isomer (13T): 1H NMR (400 MHz, CDCl3) δ 7.17-7.31 (10H, m), 6.37-6.63 (6H, m, Arom-H), 4.97 (2H, s, CH2), 4.96 (2H, s, CH2), 4.77 (H, d, 
J=8.7Hz, Hα), 4.03 (H, m, Hγ), 3.83 (H, dd, J=10.9, 4.4Hz, Hγ), 3.63 (3H, s, OMe), 3.62 (3H, s, OMe), 2.92 (H, dt, J=8.1, 4.7Hz, Hβ). 13C NMR 
(100 MHz, CDCl3) δ 148.4, 148.3, 146.4, 146.0, 136.2, 136.1, 135.1, 131.4, 127.5, 126.8, 126.2, 119.3, 117.8, 113.0, 112.5, 111.8, 109.3, 78.3 
(Cα), 70.0 (CH2), 69.9 (CH2), 65.3 (Cγ), 55.0 (OMe), 54.9 (OMe), 53.5 (Cβ) ppm. Erythro isomer (13E): 1H NMR (400 MHz, CDCl3) δ 7.17-7.35 
(10H, m), 6.57-6.74 (6H, m, Arom-H), 5.03 (4H, s, 2xCH2), 4.81 (H, d, J=6.6Hz, Hα), 3.70 (3H, s, OMe), 3.67 (3H, s, OMe), 3.66-3.70 (H, m, 
Hγ), 3.63 (H, dd, J=10.9, 6.6Hz, Hγ), 2.97 (H, t, J=6.6Hz, Hβ). 13C NMR (100 MHz, CDCl3) δ 148.6, 148.5, 146.7, 146.5, 136.2, 136.1, 134.0, 
130.4, 127.51, 127.5, 126.8, 126.2, 120.0, 117.9, 113.1, 112.7, 112.1, 109.3, 74.7 (Cα), 70.04 (CH2), 70.03 (CH2), 63.1 (Cγ), 55.0 (OMe), 54.9 
(OMe), 54.0 (Cβ) ppm. 
 
Deprotection (compound 14, DGPD, Figure S16-17)  
To the solution of compound 13T-threo (196 mg, 0.392 mmol) in 5 ml of methanol, 10% Pd-C (80 mg) was added and stirred 4.5 hours under H2 
atmosphere. The reaction mixture was filtered, and the filtrate was dried to obtain a crude oil. The mixture was purified by preparative TLC 
developed with ethyl acetate/hexane (2:1, v/v) to obtain a white powder (compound 14T, 118 mg, 94.4 mol%). To the solution of compound 13E-
erythro (112 mg, 0.224 mmol) in 12 mL of methanol/THF (1:1, v/v), 10% Pd-C (80 mg) was added and stirred for 6 hours under H2 atmosphere to 
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obtain a crude oil. The crude oil was purified by preparative TLC developed with ethyl acetate to obtain a syrup (compound 14E, 46.0 mg, 64.0 
mol%). Threo isomer (14T): 1H NMR (400 MHz, CD3OD) δ 6.47-6.62 (6H, m, Arom-H), 4.79 (H, d, J=8.7Hz, Hα), 4.09 (H, dd, J=10.9, 6.7Hz, 
Hγ), 3.90 (H, dd, J=10.8, 6.6Hz, Hγ), 3.68 (3H, s, OMe), 3.67 (3H, s, OMe), 2.98 (H, dt, J=8.7, 6.7Hz, Hβ). 13C NMR (100 MHz, CD3OD) δ 148.5 
(C3), 148.4 (C3’), 146.7 (C4), 146.2 (C4’), 136.3 (C1), 132.8 (C1’), 122.6 (C6’), 120.8 (C6), 115.9 (C5’), 115.5 (C5), 114.4 (C2’), 112.2 (C2), 
78.5 (Cα), 65.9 (Cγ), 56.53 (Cβ), 56.47 (OMe), 56.4 (OMe) ppm. Erythro isomer (14E): 1H NMR (400 MHz, CD3OD) δ 6.60-6.71 (6H, m, Arom-
H), 4.92 (H, d, J=5.7Hz, Hα), 3.84 (H, dd, J=10.8, 6.6Hz, Hγ), 3.75 (3H, s, OMe), 3.69 (3H, s, OMe), 3.69 (H, dd, J=10.8, 6.6Hz, Hγ), 2.91 (H, dt, 
J=6.7, 5.7Hz, Hβ). 13C NMR (100 MHz, CD3OD) δ 148.6 (C3), 148.5 (C3’), 146.7 (C4), 146.4 (C4’), 136.6 (C1), 132.4 (C1’), 123.3 (C6’), 120.5 
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